Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:activeDuring |
gptkb:Pantoprazole
|
| gptkbp:availableFormats |
Tablet
Injection |
| gptkbp:brand |
gptkb:Protonix
|
| gptkbp:chemicalFormula |
C16H15F2N3O3S
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:contraindication |
Severe liver disease
Hypersensitivity to pantoprazole |
| gptkbp:date |
2000
|
| gptkbp:dosageForm |
Enteric-coated tablet
Lyophilized_powder_for_injection |
| gptkbp:drugInterdiction |
Proton pump inhibitor
|
| gptkbp:duration |
24 hours
|
| gptkbp:formulation |
Injectable solution
Delayed-release tablet |
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:hasFilm |
Clostridium difficile infection
Low magnesium levels Kidney problems |
| https://www.w3.org/2000/01/rdf-schema#label |
Pantozol
|
| gptkbp:inheritsFrom |
1 hour
|
| gptkbp:interactsWith |
Warfarin
Digoxin Clopidogrel Methotrexate |
| gptkbp:isATypeOf |
138786-67-1
|
| gptkbp:lastProduced |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mandates |
Erosive esophagitis
Pathological hypersecretion of gastric acid |
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:marketSegment |
Prescription only
|
| gptkbp:numberOfStudents |
1 hour
|
| gptkbp:nutritionalValue |
Liver
|
| gptkbp:operates_in |
A02BC02
|
| gptkbp:route |
Intravenous
Oral |
| gptkbp:sideEffect |
Diarrhea
Nausea Vomiting Headache Abdominal pain |
| gptkbp:storage |
Room temperature
Protected from moisture |
| gptkbp:usedFor |
gptkb:Zollinger-Ellison_syndrome
Gastroesophageal reflux disease (GERD) Peptic ulcers |